Skip to main content

Table 3 Univariate analysis of prognostic factors in overall survival

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Adverse events

Median (months)

95% C.I. of median

P value

Hazard ratio

95% C.I. of HR

P value

Skin

  

.054

   

 Grade 0 (n = 32)

5.7

1.3–10.0

 

1

  

 Grade 1–2 (n = 17)

16.4

4.8–28.0

 

0.49

0.24–1.03

.059

Skin/vitiligo

  

.047

   

 Grade 0 (n = 30)

5.1

3.1–7.2

 

1

  

 Grade 1–2 (n = 19)

16.4

4.8–28.0

 

0.49

0.24–1.01

.052

Mucositis

  

.150

   

 Grade 0 (n = 46)

11.3

5.6–17.0

 

1

  

 Grade 1–2 (n = 3)

6.0

0.1–13.2

 

2.36

0.71–7.92

.163

Colitis

  

.773

   

 Grade 0 (n = 43)

13.1

6.9–19.4

 

1

  

 Grade 1–2 (n = 6)

9.7

2.716.6

 

1.15

0.44–2.98

.773

Liver

  

.292

   

 Grade 0 (n = 47)

10.7

5.3–16.2

 

1

  

 Grade 1–2 (n = 1)

9.7

–

 

1.55

0.21–11.50

.670

 Grade 3–5 (n = 1)

2.8

–

 

4.33

0.55–33.91

.162

Lung

  

.001

   

 Grade 0 (n = 47)

10.7

6.2–15.3

 

1

  

 Grade 3–5 (n = 2)

0.9

–

 

8.90

1.83–43.4

.007

Endocrine

  

.062

   

 Grade 0 (n = 40)

8.8

2.4–15.3

 

1

  

 Grade 1–2 (n = 9)

18.7

2.0–35.3

 

0.38

0.13–1.09

.073

Fatigue

  

.019

   

 Grade 0 (n = 42)

11.3

6.1–16.4

 

1

  

 Grade 1–2 (n = 7)

3.7

1.3–6.2

 

2.69

1.14–6.34

.024

Vitiligo

  

.856

   

 Grade 0 (n = 47)

10.7

7.3–14.2

 

1

  

 Grade 1–2 (n = 2)

8.1

–

 

0.83

0.11–6.16

.856

Skin/vitiligo/endocrine

  

.002

   

 Grade 0 (n = 26)

4.5

0.9–8.1

 

1

  

 Any grade (n = 23)

18.7

6.2–31.1

 

0.34

0.17–0.69

.003

Overall

  

<.001

   

 Grade 0 (n = 19)

5.7

0.1–11.7

 

1

  

 Grade 1–2 (n = 27)

15.2

7.9–22.5

 

0.50

0.24–1.02

.058

 Grade 3–5 (n = 3)

2.0

0.2–3.8

 

5.13

1.29–20.34

.020

  1. C.I. confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us